By Andrew Silver SHANGHAI, March 6 (Reuters) - China has approved Pfizer's GLP-1 treatment Xianweiying for long-term weight ...

The small study, published recently in the journal Obesity, looked at 34 patients who had already lost weight on GLP-1 ...

New research is taking a closer look at what can happen when people stop taking GLP-1 medications for a long period of time.

GoodRx reports that GLP-1 medications will expand in use and accessibility, with new oral options and evolving insurance ...

Novo Hims strike GLP-1 deal to expand FDA-approved weight loss medication access and end legal dispute over compounded drugs.

New platform connects patients with licensed providers offering sermorelin under medical supervision, supported by a growing body of peer-reviewed research and an emerging community of clinicians and ...

As states cut Medicaid coverage for GLP-1 drugs, access to obesity treatment is increasingly tied to income—raising questions for both Medicaid and Medicare.

Uncrowned is a new destination for all things MMA, boxing, wrestling, and more, featuring Ariel Helwani. But injectable medications aren’t right for everyone. That’s where a new wave of oral GLP-1 ...

Few drugs have entered mainstream awareness as quickly or as dramatically as glucagon-like peptide-1, or GLP-1 receptor ...

SHANGHAI, March 6 (Reuters) - China has approved Pfizer's GLP-1 treatment Xianweiying for long-term weight management in overweight or obese adults, the US drugmaker said on WeChat on Friday, boosting ...

In a recent review, a small group of patients received the injections less frequently but still maintained weight loss and health benefits.